REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
13/07/2026
Voltar para busca
Dado oficial do USPTO
LIMINAL BIOSCIENCES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
LIMINAL BIOSCIENCES
ST13
US500000079293798Classe
5, 40, 42, 44, 45
Pedido
79293798
Registro
6413686
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
13/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42, 44, 45
Data de depósito
16/04/2020
Data de registro
13/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/07/2021
Última transação
13/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
CA
Examinador
WATSON, JULIE A
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Liminal BioSciences Inc.
Representantes
Timothy H. Hiebert Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infectionsfungal skin infectionsviral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disordersepilepsyalzheimer'scerebral palsyparkinson's diseasemultiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disordersalzheimer's diseaseparkinson's diseasehuntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseasesdisorders and infections of the endocrine systemgrowth and thyroid disorders; pharmaceutical preparations for the treatment of diseasesdisorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseasesdisorders and infectionsinfertilitysexually transmitted diseasesincontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseasesurological diseasesinfertilitysexually transmitted diseasesinflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseasesautoimmune diseasesimmunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseasesrespiratory infectionseye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseasesinflammatory bowel diseasesinflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disordersdiabeteshypoglycaemiagoutosteoarthritismuscular dystrophyanemia; pharmaceutical preparations for the treatment of metabolic disordersdiabetesbulimia nervosaanorexiaobesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseasesalzheimer'shuntington's diseasecerebral palsy; pharmaceutical preparations for the treatment of neurological disordersbrain injuryspinal cord injuryseizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorderscerebrovascular accidentstrokeparkinson's diseasemultiple sclerosismyasthenia gravis
Classe 40
Manufacture of pharmaceuticals to the order and specification of others
Classe 42
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals
Classe 44
Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatmentexcluding services in the field of psychology and mental health
Classe 45
Providing personal support services for families of patients with life threatening disordersemotional counseling and emotional supportcoordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
27/12/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/12/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/11/2021
FIMP
FINAL DISPOSITION PROCESSED
12/11/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
13/07/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/04/2021
PUBO
PUBLISHED FOR OPPOSITION
27/04/2021
GPNX
NOTIFICATION PROCESSED BY IB
25/04/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/04/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/03/2021
RFNT
REFUSAL PROCESSED BY IB
02/11/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/10/2020
RFRR
REFUSAL PROCESSED BY MPU
10/10/2020
MAFR
APPLICATION FILING RECEIPT MAILED
22/09/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/09/2020
CNRT
NON-FINAL ACTION WRITTEN
18/09/2020
DOCK
ASSIGNED TO EXAMINER
18/09/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/09/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
17/09/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LIMINAL BIOSCIENCES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.